Biotechnology News
UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and antibody drug conjugate (ADC)-based therapies, today announced a multi-year collaboration with Swiss pharma giant Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. 19 March 2025
US biotech Incyte has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor. 18 March 2025
Shares of US biotech 2seventy Bio skyrocketed almost 76% to $4.92 today, as it agreed to a takeover bid from US pharma major Bristol Myers Squibb, which is looking to enhance its CAR T-cell therapy business. 11 March 2025
Exclusive
Company Spotlight
Regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
Most Read
11 March 2025
25 February 2025
24 February 2025
In Brief
Swiss pharma giant Roche has announced the launch of the Roche Genentech Innovation Center Boston, USA, at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such as disease biology, engineering, and artificial intelligence / machine learning. 7 March 2025
Mergers and Acquisitions
Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm. 18 March 2025
17 March 2025
11 March 2025
10 March 2025
Editor's Pick
29 May 2024
Boardroom
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
US biotech Stoke Therapeutics, which is dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, yesterday revealed that Dr Edward Kaye has decided to step down from his role as chief executive (CEO) effective as of March 19, 2025. The firm’s shares dipped 3% following the announcement. 19 March 2025
Switzerland-headquartered iOnctura today announced the appointments of Elizabeth Holt as chief business officer (CBO) and Dr Mark Velleca as chairman of the board of directors. 17 March 2025
US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing. 14 March 2025
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze